Innovative Treatment of Inflammatory Bowel Disease Using Plant Compounds, Nanoparticles, and Gene Editing
Overcoming the Therapeutic Barrier in Inflammatory Bowel Disease
IBD (inflammatory bowel disease) is a complex disorder involving genetic predisposition, immune dysregulation, and alterations in the gut microbiota. Conventional drugs fail to achieve adequate efficacy in 30–50% of patients, making treatment selection challenging.
Plant‑Derived Compounds and Nanoparticles: A Collaborative Innovation
Plant‑derived compounds exhibit strong anti‑inflammatory, antioxidant, and immunomodulatory effects, attracting attention for IBD symptom relief. When combined with pH‑responsive and ROS‑sensitive nanoparticle delivery systems, the therapeutic agents can precisely reach the intended intestinal sites, simultaneously enhancing efficacy and tolerability.
Gene‑Based Therapies: Redesigning the Future
Loading small RNAs such as siRNA and miRNA, as well as CRISPR‑based gene‑editing technologies, onto nanoparticles enables direct modulation of inflammation‑related genes in the gut, addressing the underlying pathogenesis. This approach represents a paradigm shift by precisely suppressing immune hyper‑reactivity that conventional therapies cannot control.
Significance and Outlook
If multimodal, personalized therapies become a reality, the quality of life for IBD patients is expected to improve dramatically. With forthcoming clinical trials and regulatory alignment, these technologies are poised to become routine therapeutic options.
Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory disorder primarily affecting the gastrointestinal tract. The pathogenesis arises from complex interactions among genetic predisposition, immune dysregulation, and gut microbiota alterations. Recent advances in molecular biology, genomics, and microbiome research have identified novel therapeutic targets, enabling the development of innovative treatment strategies. Natural products derived from plants offer bioactive compounds with anti-inflammatory, antioxidant, and immunomodulatory properties, gaining attention for IBD symptom management. Conventional therapeutic management includes aminosalicylates, immunomodulators, corticosteroids, and biologics; however, 30-50% of patients show inadequate response, and oral drug delivery faces challenges due to gastrointestinal environmental heterogeneity. Recent years have witnessed substantial advances in nanoparticle-based drug delivery systems for IBD, offering improved targeting capabilities, enhanced therapeutic efficacy, and better tolerability through stimuli-responsive platforms (ROS-sensitive, pH-responsive) and active targeting strategies. Nanoparticle-mediated gene therapy, including siRNA, miRNA, and emerging CRISPR-based approaches, represents a paradigm-shifting strategy for modulating aberrant gene expression in IBD. This comprehensive review synthesizes the current understanding of IBD pathophysiology, evaluates both conventional and emerging therapeutic approaches, and provides critical analysis of advanced nanoparticle delivery systems and gene-based therapeutic strategies.
This research proposes a direct method to alleviate the suffering of inflammatory bowel disease patients who do not respond to existing treatments. Should personalized novel drugs and gene therapies become commonplace, everyone could benefit from a healthier digestive system.